Oral Oncology
Volume 38, Issue 7 , Pages 657-663 , October 2002

A conjugate of doxorubicin and an analog of Luteinizing Hormone-Releasing Hormone shows increased efficacy against oral and laryngeal cancers

  • Linda J. Krebs

      Affiliations

    • Department of Physiology and Biophysics, and Department of Oral Biology, State University of New York at Buffalo, Buffalo, NY 14214, USA
    • Institute for Lasers, Photonics and Biophotonics, Department of Chemistry, State University of New York at Buffalo, Buffalo, NY 14260, USA
    • Corresponding Author InformationCorresponding author. Present address: University of Connecticut Health Center, Center for Molecular Medicine, 263 Farmington Avenue, MC 3101, Farmington, CT 06030, USA. Tel.: +1-860-679-2668; fax: +1-860-679-1920
    • ,
  • Xiaopeng Wang

      Affiliations

    • Institute for Lasers, Photonics and Biophotonics, Department of Chemistry, State University of New York at Buffalo, Buffalo, NY 14260, USA
    • ,
  • Atilla Nagy

      Affiliations

    • Veterans Affairs Medical Center and Tulane University School of Medicine, New Orleans, LA 70112, USA
    • ,
  • Andrew V. Schally

      Affiliations

    • Veterans Affairs Medical Center and Tulane University School of Medicine, New Orleans, LA 70112, USA
    • ,
  • Paras N. Prasad

      Affiliations

    • Institute for Lasers, Photonics and Biophotonics, Department of Chemistry, State University of New York at Buffalo, Buffalo, NY 14260, USA
    • ,
  • Charles Liebow

      Affiliations

    • Department of Physiology and Biophysics, and Department of Oral Biology, State University of New York at Buffalo, Buffalo, NY 14214, USA
    • Institute for Lasers, Photonics and Biophotonics, Department of Chemistry, State University of New York at Buffalo, Buffalo, NY 14260, USA

Received 21 November 2001 ,Accepted 28 November 2001.

References 

  1. Magrath T. Targeted approaches to cancer therapy. Int J Cancer. 1997;56:163–166
  2. Schally AV, Nagy A. Cancer chemotherapy based on targeting of cytotoxic peptide conjugates to their receptors on tumors. Euro J Endocrinol. 1991;140
  3. Nagy A, Schally AV, Armatis P, Szepeshazi K, Halmos G, Kovacs M, et al.  Cytotoxic analogs of luteinizing hormone-releasing hormone containing doxorubicin or 2-pyrrolinodoxorubicin, a derivative 500–1000 times more potent. Proc Natl Acad Sci USA. 1996;93:7269–7273
  4. Emons G, Schroder B, Ortman O, Westphalen S, Schulz KD, Schally AV. High affinity binding and direct antiproliferative effects of luteinizing hormone-releasing hormone analogs in human endometrial cancer cell lines. J Clin Endocrinol Metab. 1993;77:1458–1464
  5. Schally AV, Comaru-Schally AM, Plonowski A, Nagy A, Halmos G, Rekasi Z. Peptide analogs in the therapy of prostate cancer [review]. The Prostate. 2000;45:158–166
  6. Schally AV, Nagy A, Szepeshazi K, Pinski J, Halmos G, Armatis P, et al.  In:  Filicori M,  Flamigni C editor. Treatment with Gn-RH analogs: controversies and perspectives. Carnforth, UK: Parthenon; 1996;p. 33–44
  7. Jungwirth A, Schally AV, Nagy A, Pinski J, Groot K, Galvan G, et al.  Regression of rat Dunning R-3327-H prostate carcinoma by treatment with targeted cytotoxic analog of luteinizing hormone-releasing hormone AN-207 containing 2-pyrrolinodoxorubicin. Int J Oncol. 1997;10:877–884
  8. Miyazaki M, Nagy A, Schally AV, Lamharzi N, Halmos G, Szepeshazi K, et al.  Armatis, Growth inhibition of human ovarian cancers by cytotoxic analogs of luteinizing hormone-releasing hormone. J Natl Cancer Inst. 1997;89:1803–1809
  9. Westphalen S, Kotulla G, Kaiser F, Krauss W, Werning G, Elsässer HP, et al.  Receptor mediated antiproliferative effects of the cytotoxic LHRH agonist against AN-152 in human ovarian and endometrial cancer cell lines. Int J Oncology. 2000;17:1063–1069
  10. Friess H, Buchler M, Beger HG. LH-RH receptors in the human pancreas. Basis for antihormonal treatment in ductal carcinoma of the pancreas. Int J Pancreatology. 1991;10:151–159
  11. Liebow C, Kamer AR. Receptor phosphatases and cancer (models for the therapeutic efficacy of somatostatin and LHRH analogues). Cancer J. 1992;5:200–207
  12. Crean DH, Liebow C, Lee MT, Kamer AR, Schally AV, Mang TS. Alterations in receptor-mediated kinases and phosphatases during carcinogenesis. J Cancer Res Clin Oncol. 1995;121:141–149
  13. Liebow C, Lee MT, Kamer AR, Schally AV. Regulation of luteinizing hormone releasing hormone receptor binding by heterologous and autologous receptor-stimulated (tyrosine phosphorylation. Proc Natl Acad Sci USA. 1991;88:2244–2248
  14. Lee MT, Liebow C, Kamer AR, Schally AV. Effects of epidermal growth factor and analogues of luteinizing hormone-releasing hormone and somatostatin on phosphorylation and dephosphorylation of tyrosine residues of specific protein substrates in various tumors. Proc Natl Acad Sci USA. 1991;88:1656–1660
  15. Ogier SA, Mitchell R, Fink G. Solubilization of a large molecular weight form of the rat LHRH receptor. Journal of Endocrinology. 1987;115:151–159
  16. Ishitoya J, Toriyama M, Oguchi N, Kitamura K, Ohshima M, Asano K, et al. Gene amplification and overexpression of EGF receptor in squamous cell carcinomas of the head and neck. Br J Cancer. 1989;59:559–562
  17. Saranath D, Panchal RG, Nair R, Mehta AR, Sanghavi VD, Deo MG. Amplification and overexpression of epidermal growth factor receptor gene in human oropharyngeal cancer. Eur J Cancer B Oral Oncol. 1992;28:139–143
  18. Yamada T, Takagi M, Shioda S. Evaluation of epidermal growth factor receptor in squamous call carcinoma of the oral cavity. Oral Surg Oral Med Oral Pathol. 1992;73:67–70
  19. Field JK. Oncogenes and tumor suppressor genes in squamous cell carcinoma of the head and neck. Oral Oncol Eur J Cancer. 1992;28:67–76
  20. Merlino GT, Xu YH, Richert N, Clark AJL, Ishii S, Pastan I. Elevated epidermal growth factor receptor gene copy number and expression in a squamous cell carcinoma cell line. J Clin Invest. 1985;75:1077–1079
  21. Leonard JH, Kearsley JH, Chenevix-Trench G, Hayward NK. Analysis of gene amplification in head-and-neck squamous-cell carcinoma. Int J Cancer. 1991;48:511–515
  22. Grandis JR, Tweardy DJ. Elevated levels of transforming growth factor a and epidermal growth factor receptor mesenger RNA are early markers of carcinogenesis in head and neck cancer. Cancer Res. 1993;53:3579–3584
  23. Todd R, Chou MY, Matossian K, Gallagher GT, Donoff RB, Wong DT. Cellular sources of transforming growth factor a in human oral cancer. J Dent Res. 1991;70:917–923
  24. Krebs LJ, Wang X, Pudavar HE, Bergey EJ, Schally AV, Nagy A, et al.  Regulation of targeted chemotherapy with cytotoxic lutenizing hormone-releasing hormone analogue by epidermal growth factor. Cancer Res. 2000;60:4194–4199
  25. Wang X, Krebs LJ, Al-Nun M, Pudavar H, Ghosal S, Liebow C, et al  Chemically labeled new cytotoxic agent (two-photon fluorophore for optical tracking of cellular pathway in chemotherapy). Proc Natl Acad Sci USA. 1999;96:11081–11084
  26. Ulman A, Willand CS, Kohler W, Robello DR, Williams DJ, Handley L. New sulfonyl-containing materials for nonlinear optics (semi-empirical calculations, synthesis, and properties). J Am Chem Soc. 1990;112:7083–7090
  27. Denizot F, Lang R. Rapid colorimetric assay for cell growth and survival. Modifications to the tetrazolium dye procedure giving improved sensitivity and reliability. J Immunological Methods. 1986;89:271–277
  28. Schally AV, Comaru-Schally AM. Hypothalamic and other peptide hormones. In:  Holland JR,  Frei E,  Bast RR,  Kufe DB,  Morton DL,  Weichselbaum RR editor. Cancer medicine. 5th ed.. Hamilton, Ontario BC: Decker; 2000;p. 715–726
  29. Emons G, Schally AV. The use of Luteinizing Hormone-Releasing Hormone agonists in gynecological cancer. Hum Reprod. 1994;9:1364–1379
  30. Srkalovic G, Schally AV, Wittliff JL, Day TG, Jenison EL. Presence and characteristics of receptors for [D-Trp6]LH-RH and epidermal growth factor in human ovarian cancer. Int J Oncol. 1998;12:489–498
  31. Qayum A, Gullick W, Clayton RC, Sikora K, Waxman J. The effects of gonadotropin-releasing hormone analogs in prostate cancer are mediated through specific tumor receptors. Br J Cancer. 1990;62:96–99

PII: S1368-8375(01)00130-0

Oral Oncology
Volume 38, Issue 7 , Pages 657-663 , October 2002

Article Tools

* Image Usage & Resolution